Testing novel pyrimidinyl rexinoids

A new paradigm for evaluating rexinoids for cancer prevention

Di Zhang, Ana S. Leal, Sarah Carapellucci, Pritika H. Shahani, Jaskaran S. Bhogal, Samir Ibrahim, San Raban, Peter Jurutka, Pamela Marshall, Michael B. Sporn, Carl Wagner, Karen T. Liby

Research output: Contribution to journalArticle

Abstract

Rexinoids, selective ligands for retinoid X receptors inflammatory activities of rexinoids. We reveal new (RXR), have shown promise in preventing many types immunomodulatory actions of the above rexinoids, of cancer. However, the limited efficacy and undesir-especially their ability to diminish the percentage of able lipidemic side-effects of the only clinically macrophages and myeloid-derived suppressor cells in approved rexinoid, bexarotene, drive the search for the lung and to redirect activation of M2 macro-new and better rexinoids. Here we report the evalu-phages. The rexinoids also potently inhibit critical ation of novel pyrimidinyl (Py) analogues of two inflammatory mediators including IL6, IL1b, CCL9, known chemopreventive rexinoids, bexarotene (Bex) and nitric oxide synthase (iNOS) induced by lipo- and LG100268 (LG268) in a new paradigm. We show polysaccharide. Moreover, in vitro iNOS and SREBP that these novel derivatives were more effective agents (sterol regulatory element-binding protein) induction than bexarotene for preventing lung carcinogenesis assays correlate with in vivo efficacy and toxicity, induced by a carcinogen. In addition, these new respectively. Our results not only report novel pyrim-analogues have an improved safety profile. PyBex idine derivatives of existing rexinoids, but also caused less elevation of plasma triglyceride levels than describe a series of biological screening assays that bexarotene, while PyLG268 reduced plasma choles-will guide the synthesis of additional rexinoids. Fur-terol levels and hepatomegaly compared with ther progress in rexinoid synthesis, potency, and safe-LG100268. Notably, this new paradigm mechanistity should eventually lead to a clinically acceptable and cally emphasizes the immunomodulatory and anti-useful new drug for patients with cancer.

Original languageEnglish (US)
Pages (from-to)211-224
Number of pages14
JournalCancer Prevention Research
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Neoplasms
Sterol Regulatory Element Binding Proteins
Retinoid X Receptors
Lung
Hepatomegaly
Nitric Oxide Synthase
Biological Assay
Carcinogens
Bacteriophages
Polysaccharides
Interleukin-6
Carcinogenesis
Triglycerides
Macrophages
Ligands
Safety
bexarotene
Pharmaceutical Preparations
LG 100268
Myeloid-Derived Suppressor Cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zhang, D., Leal, A. S., Carapellucci, S., Shahani, P. H., Bhogal, J. S., Ibrahim, S., ... Liby, K. T. (2019). Testing novel pyrimidinyl rexinoids: A new paradigm for evaluating rexinoids for cancer prevention. Cancer Prevention Research, 12(4), 211-224. https://doi.org/10.1158/1940-6207.CAPR-18-0317

Testing novel pyrimidinyl rexinoids : A new paradigm for evaluating rexinoids for cancer prevention. / Zhang, Di; Leal, Ana S.; Carapellucci, Sarah; Shahani, Pritika H.; Bhogal, Jaskaran S.; Ibrahim, Samir; Raban, San; Jurutka, Peter; Marshall, Pamela; Sporn, Michael B.; Wagner, Carl; Liby, Karen T.

In: Cancer Prevention Research, Vol. 12, No. 4, 01.04.2019, p. 211-224.

Research output: Contribution to journalArticle

Zhang, D, Leal, AS, Carapellucci, S, Shahani, PH, Bhogal, JS, Ibrahim, S, Raban, S, Jurutka, P, Marshall, P, Sporn, MB, Wagner, C & Liby, KT 2019, 'Testing novel pyrimidinyl rexinoids: A new paradigm for evaluating rexinoids for cancer prevention', Cancer Prevention Research, vol. 12, no. 4, pp. 211-224. https://doi.org/10.1158/1940-6207.CAPR-18-0317
Zhang, Di ; Leal, Ana S. ; Carapellucci, Sarah ; Shahani, Pritika H. ; Bhogal, Jaskaran S. ; Ibrahim, Samir ; Raban, San ; Jurutka, Peter ; Marshall, Pamela ; Sporn, Michael B. ; Wagner, Carl ; Liby, Karen T. / Testing novel pyrimidinyl rexinoids : A new paradigm for evaluating rexinoids for cancer prevention. In: Cancer Prevention Research. 2019 ; Vol. 12, No. 4. pp. 211-224.
@article{3c9ec7ba923545b4a4df55fd2d7e0108,
title = "Testing novel pyrimidinyl rexinoids: A new paradigm for evaluating rexinoids for cancer prevention",
abstract = "Rexinoids, selective ligands for retinoid X receptors inflammatory activities of rexinoids. We reveal new (RXR), have shown promise in preventing many types immunomodulatory actions of the above rexinoids, of cancer. However, the limited efficacy and undesir-especially their ability to diminish the percentage of able lipidemic side-effects of the only clinically macrophages and myeloid-derived suppressor cells in approved rexinoid, bexarotene, drive the search for the lung and to redirect activation of M2 macro-new and better rexinoids. Here we report the evalu-phages. The rexinoids also potently inhibit critical ation of novel pyrimidinyl (Py) analogues of two inflammatory mediators including IL6, IL1b, CCL9, known chemopreventive rexinoids, bexarotene (Bex) and nitric oxide synthase (iNOS) induced by lipo- and LG100268 (LG268) in a new paradigm. We show polysaccharide. Moreover, in vitro iNOS and SREBP that these novel derivatives were more effective agents (sterol regulatory element-binding protein) induction than bexarotene for preventing lung carcinogenesis assays correlate with in vivo efficacy and toxicity, induced by a carcinogen. In addition, these new respectively. Our results not only report novel pyrim-analogues have an improved safety profile. PyBex idine derivatives of existing rexinoids, but also caused less elevation of plasma triglyceride levels than describe a series of biological screening assays that bexarotene, while PyLG268 reduced plasma choles-will guide the synthesis of additional rexinoids. Fur-terol levels and hepatomegaly compared with ther progress in rexinoid synthesis, potency, and safe-LG100268. Notably, this new paradigm mechanistity should eventually lead to a clinically acceptable and cally emphasizes the immunomodulatory and anti-useful new drug for patients with cancer.",
author = "Di Zhang and Leal, {Ana S.} and Sarah Carapellucci and Shahani, {Pritika H.} and Bhogal, {Jaskaran S.} and Samir Ibrahim and San Raban and Peter Jurutka and Pamela Marshall and Sporn, {Michael B.} and Carl Wagner and Liby, {Karen T.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1158/1940-6207.CAPR-18-0317",
language = "English (US)",
volume = "12",
pages = "211--224",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Testing novel pyrimidinyl rexinoids

T2 - A new paradigm for evaluating rexinoids for cancer prevention

AU - Zhang, Di

AU - Leal, Ana S.

AU - Carapellucci, Sarah

AU - Shahani, Pritika H.

AU - Bhogal, Jaskaran S.

AU - Ibrahim, Samir

AU - Raban, San

AU - Jurutka, Peter

AU - Marshall, Pamela

AU - Sporn, Michael B.

AU - Wagner, Carl

AU - Liby, Karen T.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Rexinoids, selective ligands for retinoid X receptors inflammatory activities of rexinoids. We reveal new (RXR), have shown promise in preventing many types immunomodulatory actions of the above rexinoids, of cancer. However, the limited efficacy and undesir-especially their ability to diminish the percentage of able lipidemic side-effects of the only clinically macrophages and myeloid-derived suppressor cells in approved rexinoid, bexarotene, drive the search for the lung and to redirect activation of M2 macro-new and better rexinoids. Here we report the evalu-phages. The rexinoids also potently inhibit critical ation of novel pyrimidinyl (Py) analogues of two inflammatory mediators including IL6, IL1b, CCL9, known chemopreventive rexinoids, bexarotene (Bex) and nitric oxide synthase (iNOS) induced by lipo- and LG100268 (LG268) in a new paradigm. We show polysaccharide. Moreover, in vitro iNOS and SREBP that these novel derivatives were more effective agents (sterol regulatory element-binding protein) induction than bexarotene for preventing lung carcinogenesis assays correlate with in vivo efficacy and toxicity, induced by a carcinogen. In addition, these new respectively. Our results not only report novel pyrim-analogues have an improved safety profile. PyBex idine derivatives of existing rexinoids, but also caused less elevation of plasma triglyceride levels than describe a series of biological screening assays that bexarotene, while PyLG268 reduced plasma choles-will guide the synthesis of additional rexinoids. Fur-terol levels and hepatomegaly compared with ther progress in rexinoid synthesis, potency, and safe-LG100268. Notably, this new paradigm mechanistity should eventually lead to a clinically acceptable and cally emphasizes the immunomodulatory and anti-useful new drug for patients with cancer.

AB - Rexinoids, selective ligands for retinoid X receptors inflammatory activities of rexinoids. We reveal new (RXR), have shown promise in preventing many types immunomodulatory actions of the above rexinoids, of cancer. However, the limited efficacy and undesir-especially their ability to diminish the percentage of able lipidemic side-effects of the only clinically macrophages and myeloid-derived suppressor cells in approved rexinoid, bexarotene, drive the search for the lung and to redirect activation of M2 macro-new and better rexinoids. Here we report the evalu-phages. The rexinoids also potently inhibit critical ation of novel pyrimidinyl (Py) analogues of two inflammatory mediators including IL6, IL1b, CCL9, known chemopreventive rexinoids, bexarotene (Bex) and nitric oxide synthase (iNOS) induced by lipo- and LG100268 (LG268) in a new paradigm. We show polysaccharide. Moreover, in vitro iNOS and SREBP that these novel derivatives were more effective agents (sterol regulatory element-binding protein) induction than bexarotene for preventing lung carcinogenesis assays correlate with in vivo efficacy and toxicity, induced by a carcinogen. In addition, these new respectively. Our results not only report novel pyrim-analogues have an improved safety profile. PyBex idine derivatives of existing rexinoids, but also caused less elevation of plasma triglyceride levels than describe a series of biological screening assays that bexarotene, while PyLG268 reduced plasma choles-will guide the synthesis of additional rexinoids. Fur-terol levels and hepatomegaly compared with ther progress in rexinoid synthesis, potency, and safe-LG100268. Notably, this new paradigm mechanistity should eventually lead to a clinically acceptable and cally emphasizes the immunomodulatory and anti-useful new drug for patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=85064041623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064041623&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-18-0317

DO - 10.1158/1940-6207.CAPR-18-0317

M3 - Article

VL - 12

SP - 211

EP - 224

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 4

ER -